Denosumab or zoledronic acid (ZA) therapy on pain interference and cancer-specific quality of life (CSQoL) in patients with castrate-resistant prostate cancer (CRPC) and bone metastases (BM).
Donald Patrick
Consultant or Advisory Role - Amgen
Charles S. Cleeland
Consultant or Advisory Role - Amgen
Lesley Fallowfield
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Matthew Raymond Smith
Consultant or Advisory Role - Amgen
Laurence Klotz
Honoraria - Amgen (I); Ferring; Janssen-Ortho; Sanofi
Research Funding - Ferring
Stephane Oudard
Consultant or Advisory Role - Bayer; Janssen; Novartis; Pfizer; Sanofi ; Takeda
Honoraria - Bayer; Janssen; Novartis; Pfizer; Sanofi ; Takeda
Gavin M. Marx
Consultant or Advisory Role - Amgen; Sanofi
Honoraria - Amgen; Sanofi
Research Funding - Amgen
Rachel Wei
Stock Ownership - Amgen
Research Funding - Amgen
Katarina Ohrling
Stock Ownership - Amgen
Research Funding - Amgen
Yi Qian
Stock Ownership - Amgen
Research Funding - Amgen